Syndax Pharmaceuticals Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, we're going to go ahead and get started. I'm Stephen Willey, one of the Senior Biotech Analysts here at Stifel, and glad to have with us in the next session, Syndax. We have Michael Metzger, CEO. We have Nick Botwood, who's the CMO. We have the new CFO in attendance as well, Aaron Ondrey. We're just going to have a discussion. If anyone has a question, feel free to raise your hand, and we'll get you acknowledged and your question answered. Mike and Nick, I appreciate you guys coming, and just any opening statements you might want to make before we jump into Q&A.
Well, first, Steve, nice to see you. Thanks for having us. As always, great to be here. Look, I think we're in a great position as a company. I think we've had a commercial effort over the last seven-plus quarters, and growth for two products now, within the heme space for Revuforj in KMT2A and NPM1 acute leukemia. The quarterly report showed growth in revenue, growth in new patients, leading in all categories, really a dominant position within the menin class and growing. We feel very good about the trajectory there. For Niktimvo, very similar story, growth, 12% revenue. We're seeing patient growth, as well as extension duration. We're pacing very well with both franchises, moving as quickly as we can towards profitability with some very disciplined spending around our portfolio, with aspirations to get to frontline coming soon.
We're very excited about the commercial business and now the emerging pipeline that we have, which we talked about this summer, an EGFR inhibitor going into the clinic in the fourth quarter, this quarter. We think that could be a highly differentiated asset with a very significant market opportunity, and then, of course, the next-gen menin going into MF. We have lots to come, exciting time coming at ASH as well, which we'll talk about today, and a lot of data to get through.
Good luck. All right. Yeah.
I generally do not like to start these things off talking about a competitor asset.
Yeah. But there's obviously been a bit of a visceral reaction to the headline efficacy data we saw in the ASH abstract last week for J&J's bleximenib.
Let's just get that out of the way. Obviously, not a lot of information or context in the abstract itself, but would just be curious to kind of hear your perspective on it and how you've been messaging this to investors.
Well, let me just start off by saying a couple things, then I'll maybe pass it to Nick for his thoughts on their abstract. Keep in mind that we've been in this market for three years. We're the market leader. We have a dominant position in relapse refractory. We've shown more data in combination, which is where this whole field is going. I think it's going to be very hard to beat our profile from an efficacy, safety, tolerability, and breadth standpoint, breadth of data. I think it's one abstract. It's a little early. We're actually very excited about our position and how we go into ASH this year. But just keep in mind that this is a company that's three years behind us. While it's J&J, we feel we're very well competitively positioned to continue to win here. Nick, maybe. Well, thank you.
Thank you, Steve. Good to see you. Thank you for the invitation and the question. Just to add to what Michael was saying, I would say that the treatment of relapse refractory AML has been transformed in the last three years. I think it's really important to remember that when we pioneered in this space three, four years ago, and we did our original AUGMENT study, the treatment of AML was very different from as it is now. The first thing to say is it's really not any sort of comparison with J&J. It's a completely different paradigm now. That, of course, is reflected in the demographics of the patients going into the study. It's a much less heavily pre-treated number of patients.
The median may be the same, but if you look at the percentage of patients that had three or four lines plus, in AUGMENT, we had patients out to 11 lines of therapy. Many of these patients were sadly likely on the way to hospice care when they were offered, at that point, an experimental therapy. In the three years since we've been on the market, we've really transformed outcomes. Patients are now getting treated in combinations, they're getting treated earlier in their treatment paradigms, they're going to transplant more regularly, and they're going on to maintenance therapy after transplant. I think that's most likely what you see in some of the competitor data that is reading out now, three years after we did our studies.
If you actually compare more relevantly, I think, to the two real-world series we will be having and being presenting at ASH, and you look for the CR/CRh and the response rates of those patients, both monotherapy and in combination, you'll see it much more comparable to some of the competitor data reading out now. That's a much more reasonable comparison than a data set that was done three years ago. I also think, and people react to an abstract, abstracts are difficult to make sense of. These are complicated data sets. You really need to understand the totality of the data. You need to understand how the evaluable efficacy, evaluable population was defined. Many more patients went into some of these competitor studies than were actually included in the efficacy evaluable population. That, of course, can impact the numerical aspect of CR/CRh.
We're excited to see the menin field moving forward, of course, but we want to make sure that we've really understood the data. The other thing we don't talk about very much, but is important for these patients, is, of course, the benefit-risk trade-off. We know some of these newer menin molecules actually have very potent profiles, and of course, that translates into some of the on-target toxicity issues that you can see, specifically increased rates of differentiation syndrome, sometimes requiring a dose titration up and careful management initially while patients are on therapy, and also higher rates of cytopenias. We know now, because of the pioneering work we did with John Crispino, we may come back to that a little later, that the impact on thrombocytopenia, in particular, is an on-target effect of menin inhibition.
As you would expect with a potent asset dosed high, you do see very high rates of cytopenias as a monotherapy. Why is that relevant? Well, the field is moving to combinations. That is very clear. Most of our real-world series now are treated technically off-label because physicians want to get high response rate, and they treat in combinations with venetoclax or Ven, single agent or other standards of care. We know that revumenib combines very readily, and indeed, we'll have three data sets at ASH looking at frontline combinations showing very tolerable regimens and very high levels of efficacy.
We haven't seen any combination data from some of the other menins yet, and I think that's an important question because as the field moves forwards, monotherapy data may very soon be less relevant than combinations, whether that be in newly diagnosed patients or treating patients in the relapse refractory setting. We're extremely happy with our leadership and the presence we'll have at ASH, and I think there are a lot of questions and unknowns still to be figured out for some of the newer menins coming through.
Yeah. No, I think all good points. I guess when I look at what both you and J&J are doing in the frontline setting, right? You both have registrational studies ongoing. I think you both have the Ven/Aza combo in frontline on fit patients. You have an IC combo in frontline fit patients. But there are some nuanced design differences there. Maybe you can just talk about those a little bit, just given the emphasis that we're kind of moving to combinations. Then what's the strategic rationale kind of underlying those differences?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
